Abstract 3016
Background
Although dedicated breast PET (DbPET) visualizes sub-centimeter breast cancer lesions and intratumoral heterogeneity, the impact of histology on the detectability of DbPET remains unknown.
Methods
This study included 455 patients with breast cancer, who underwent whole-body PET (WBPET) and ring-type DbPET between January 2016 and March 2018. The relationship of histology and sensitivities of WBPET and DbPET for breast cancer was assessed.
Results
The median patient age was 57 years and histology was as follows: 82 (18.0%) noninvasive carcinoma, 18 (4.0%) microinvasive carcinoma, 305 (67.0%) invasive carcinoma with no special type, 9 (2.0%) invasive lobular carcinoma, and 41 (9.0%) other types. The sensitivity of WBPET and DbPET was 74.5% and 93.2%, respectively. The sensitivities of each histology on WBPET/DbPET were 41.5%/78.0%, 72.2%/100%, 83.9%/96.7%, 44.4%/88.9%, and 78.0%/95.1%, respectively (Table). The sensitivity was low on WBPET in noninvasive, microinvasive, invasive lobular, mucinous and tubular carcinomas. Lobular carcinoma in situ had low sensitivity on both WBPET and DbPET imaging. In the multivariate analysis, undetectable tumor factors on WBPET were sub-centimeter tumor size (Odds ratio [OR] = 6.04, P < 0.001) and histology (OR = 1.69, P = 0.08); for DbPET, Ki-67 labeling index was an undetectable tumor factor (OR = 4.32, P = 0.039).Table: 1343P
Sensitivities of whole-body and dedicated breast PET according to histology
| N | Sensitivity (%) | P | ||
|---|---|---|---|---|
| WbPET | DbPET | |||
| Total | 455 | 339 (74.5) | 424 (93.2) | < 0.001 |
| Noninvasive carcinoma | 82 | 34 (41.5) | 64 (78.0) | < 0.001 |
| Ductal carcinoma in situ | 72 | 32 (44.4) | 61 (84.7) | < 0.001 |
| Lobular carcinoma in situ | 8 | 1 (12.5) | 2 (25.0) | 1 |
| Others | 2 | 1 (50.0) | 1 (50.0) | 1 |
| Microinvasive carcinoma | 18 | 13 (72.2) | 18 (100) | 0.046 |
| Invasive carcinoma of no special type | 305 | 256 (83.9) | 295 (96.7) | < 0.001 |
| Invasive lobular carcinoma | 9 | 4 (44.4) | 8 (88.9) | 0.131 |
| Others | 41 | 32 (78.0) | 39 (95.1) | 0.048 |
| Mucinous carcinoma | 19 | 13 (68.4) | 18 (94.7) | 0.09 |
| Tubular carcinoma | 5 | 3 (60.0) | 4 (80.0) | 0.444 |
| Carcinoma with apocrine differentiation | 5 | 5 (100) | 5 (100) | 1 |
| Invasive micropapillary carcinoma | 5 | 5 (100) | 5 (100) | 1 |
| Others | 7 | 6 (85.7) | 7 (100) | 1 |
Conclusions
Breast cancers with the specific histological subtypes are hard to detect on WBPET. DbPET can overcome the factors for weak WBPET detectability, such as tumor size and histology, and might prevent the overdiagnosis of lobular carcinoma in situ.
Clinical trial identification
Legal entity responsible for the study
Hiroshima University.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract